http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013. http://medicalxpress.com/news/2013-04-xl-cabozantinib-for-colorectal-cancer.html Cancer Mon, 08 Apr 2013 13:00:04 EST news284633351 (Medical Xpress)—UC Irvine-led studies have revealed the cellular mechanism by which circadian rhythms – also known as the body clock – modify energy metabolism and also have identified novel compounds that control this action. The findings point to potential treatments for disorders triggered by circadian rhythm dysfunction, ranging from insomnia and obesity to diabetes and cancer. http://medicalxpress.com/news/2013-01-circadian-rhythms-potential-treatment-disorders.html Cardiology Tue, 22 Jan 2013 15:12:20 EST news278089921 A compound from the South African toothbrush tree inactivates a drug target for tuberculosis in a previously unseen way. http://medicalxpress.com/news/2013-01-medicinal-toothbrush-tree-yields-antibiotic.html Diseases, Conditions, Syndromes Mon, 14 Jan 2013 09:09:24 EST news277376947 (Medical Xpress)—Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded £1.4 million to design a new drug for the treatment of chronic pain. http://medicalxpress.com/news/2012-08-drug-chronic-pain.html Medical research Fri, 24 Aug 2012 09:40:01 EST news265018693 In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch. http://medicalxpress.com/news/2011-09-scientists-class-anti-diabetic-compound.html Medical research Sun, 04 Sep 2011 13:00:07 EST news234359780